Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 5837

Next Previous
X
Search
Drug Profile

REGN 5837

Alternative Names: Anti-CD22 x Anti-CD28 co-stimulatory bispecific monoclonal antibody; REGN-5837

Latest Information Update: 09 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 12 Apr 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (Parenteral) (NCT05685173)
  • 13 Jan 2023 Regeneron Pharmaceuticals plans a phase I ATHENA-1 trial for Non-Hodgkins lymphoma (Combination therapy, Second-line therapy or greater) in March 2023 (IV, infusion) (NCT05685173) (EudraCT2020-005084-32)
  • 14 Dec 2022 Preclinical trials in Non-Hodgkin's lymphoma (Combination therapy) in USA (IV) prior to December 2022

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top